FindTrial
Sign In

An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine

BHV3000-401: An Open-label, Intermediate-size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03934086
Enrollment
Unknown
Registered
2019-05-01
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

Migraine prevention, phonophobia, photophobia, nausea

Brief summary

The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data. (NOTE: ONLY FOR PATIENTS who participated in a previous BHV-3000/Rimegepant Clinical Trial in the past)

Interventions

DRUGrimegepant

rimegepant 75 mg

Sponsors

Pfizer
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1.Subjects who have completed any BHV3000 (rimegepant) clinical study without significant protocol violations.

Exclusion criteria

1. History of basilar migraine or hemiplegic migraine 2. History with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease 3. HIV history 4. Uncontrolled hypertension or uncontrolled diabetes 5. Current diagnosis of major depression, other pain syndromes, psychiatric conditions (e.g., schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments 6. History of gastric, or small intestinal surgery, or has a disease that causes malabsorption

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026